RxDoctor Payments Data

Holly Callaway

Gerontology · Mountain Brk, ALNPI 1114693363

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Boston Scientific at 25.3% of the total.

$1,930in general payments, 2019–2025

Across 80 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$488
  • Collegium Pharmaceutical, Inc.$466
  • AbbVie$191
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$151
  • Scilex Pharmaceuticals Inc.$124
  • Amgen$79
  • plus $431 from 16 others

What the payments were for

  • Food & beverage$1,930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,930 in reported general payments places this provider in the 75th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$43,444
Medicare patients
168
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine105$32,663
BelbucaBuprenorphine Hcl46$32,207
GraliseGabapentin13$12,827
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen508$12,713
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen367$11,312
Pregabalin412$9,990
Gabapentin755$9,137
SavellaMilnacipran Hcl12$5,704
Tizanidine Hcl459$5,495
Methocarbamol352$5,151
Lidocaine28$3,759
Diclofenac Sodium153$3,689
Tramadol Hcl ErTramadol Hcl33$3,464
Cyclobenzaprine Hcl234$2,508
Duloxetine Hcl144$2,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine$20$32,663105 claims
Collegium Pharmaceutical, Inc.Belbuca$466$32,20746 claims
Almatica Pharma LLCGralise$59$12,82713 claims
AbbVieSavella$191$5,70412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 143 gerontology providers in Alabama.

Other gerontology in Mountain Brk

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →